ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pain"

  • Abstract Number: 0756 • ACR Convergence 2023

    Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative

    Banafshe Felfeliyan1, Stephanie Wichuk2, Abhilash Hareendranathan3, Janet Ronsky4 and Jacob Jaremko2, 1University of Alberta, Calgary, AB, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Radiology and Diagnostic Imaging, Edmonton, AB, Canada, 4University of Calgary, Calgary, AB, Canada

    Background/Purpose: Knee effusion-synovitis (ES) is an attractive target for therapeutic interventions in arthritis, since it is associated with stiffness, pain, and disease progression to arthroplasty.…
  • Abstract Number: 1189 • ACR Convergence 2023

    Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis

    Carly Conran1, Larry Moreland2, Andrew Clauw1, Jennifer Seifert1, Carson Keeter3, Craig Hogan1 and Michael Dayton1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Colorado, Denver, CO, 3University of Colorado, Aurora, CO

    Background/Purpose: Chronic pain in patients with hip and knee osteoarthritis (OA) has been classically attributed to nociceptive pain pathways. Emerging evidence has demonstrated influence from…
  • Abstract Number: 1609 • ACR Convergence 2023

    Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study

    Danilo Perretta1, Daniele Mauro1, flavia riccio1, valentina marino1, emma scoppetta2, Francesco ciccia1 and rosella tirri1, 1University of Campania - Luigi Vanvitelli, Naples, Italy, 2University of Salerno, Salerno, Italy

    Background/Purpose: SARS-CoV-2 infection has been increasingly recognized for its potential neurological manifestations. Fibromyalgia (FM) patients, who already experience neuropathic pain, may be particularly vulnerable to…
  • Abstract Number: 1839 • ACR Convergence 2023

    Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting

    Styliani Tsiami1, Elena Enax-Krumova2, Dietrich Sturm3, Matthias Vorgerd2, Bjoern Buehring4, Juergen Braun5 and Xenofon Baraliakos1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 2Neurologische Klinik Universitätsklinikum Bergmannsheil Bochum, Ruhr-University Bochum, Bochum, Germany, 3Agaplesion Bethesda - Krankenhaus, Wuppertal, Klinik für Neurologie, Wuppertal, Germany, 4Krankenhaus St. Josef, Wuppertal, Klinik für Internistische Rheumatologie, Wuppertal, Germany, 5Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: Small fiber neuropathy (SFN), a polyneuropathy (PNP) affecting A-delta and C-fibers has been described in patients with fibromyalgia (FM). Different patterns of small fiber…
  • Abstract Number: 2157 • ACR Convergence 2023

    Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis

    Maxime Dougados1, Peter C. Taylor2, David Gruben3 and Meriem Kessouri4, 1Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, 2Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Pfizer Inc., Groton, CT, 4Pfizer Inc., Paris, France

    Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…
  • Abstract Number: 0314 • ACR Convergence 2023

    Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial

    Leonard Kapural1, Stephen D. Collins2, Eric Grigsby3, Mark McBride4, Jayson Rieger5, Morgan Stokes6, Howard Rutman6 and Flavia Cicuttini7, 1Center for Clinical Research, Winston-Salem, NC, 2Xalud Therapeutics, Inc., Chicago, IL, 3Neurovations Clinical Research, Napa, CA, 4Instat Clinical Research, Chatham, NJ, 5PBM Capital, Charlottesville, VA, 6Xalud Therapeutics, Inc., Berkeley, CA, 7Monash University, Melbourne, Australia

    Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to…
  • Abstract Number: 0817 • ACR Convergence 2023

    Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)

    Bedru Abafita1, Ambrish Singh1, Dawn Aitken1, Steffany Moonaz2, Andrew J Palmer1, Leigh Blizzard1, Changhai Ding1, Stan Drummen1, Graeme Jones3, Kim Bennell4 and Benny Samuel Antony1, 1Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 2Department of Clinical and Health Services Research, Southern California University of Health Sciences, Whittier, CA, 3Menzies Institute for Medical Research, University of Tasmania, Melbourne, Australia, 4University of Melbourne, Melbourne, Australia

    Background/Purpose: There is uncertainty about the best type of exercise to optimise outcomes for people with knee osteoarthritis (OA). Strengthening exercise is commonly recommended. However,…
  • Abstract Number: 1191 • ACR Convergence 2023

    A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee

    Guang-Liang Jiang1 and Feng Xu2, 1Xgene Pharmaceutical Inc., Lexington, MA, 2Xgene Pharmaceutical Inc., Altos Hills, CA

    Background/Purpose: Globally osteoarthritis affects about 302 million patients, knee osteoarthritis accounts for 263 million and ranks the highest in disability and pain compared to OA…
  • Abstract Number: 1610 • ACR Convergence 2023

    Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial

    Michael Gendreau1, Andrea Chadwick2, Lance McCracken3, David Williams4, Daniel Clauw5, Juan Luciano6, Yifei Dai7, Nicolette Vega8, Zunera Ghalib8, Kristen Guthrie8, Allison Kraus8, Michael Rosenbluth8, Jennifer Zomnir9, Dana Reddy10 and Lesley arnold11, 1Gendreau Consulting, LLC, Poway, CA, 2Department of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas School of Medicine, Kansas City, KS, 3Department of Psychology, Uppsala University, Uppsala, Sweden, 4Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, 5Department of Anesthesiology, University of Michigan, Ann Arbor, MI, 6Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona, Barcelona, Spain, 7Swing Therapeutics, Gainesville, FL, 8Swing Therapeutics, San Francisco, CA, 9DelRicht Resesarch, Mckinney, TX, 10Curavit, Scarsdale, NY, 11Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH

    Background/Purpose: Acceptance and Commitment Therapy (ACT), a form of guideline-recommended Cognitive Behavioral Therapy (CBT), has been empirically validated as a non-drug treatment for fibromyalgia (FM).…
  • Abstract Number: 1844 • ACR Convergence 2023

    Are Patients with Inflammatory Rheumatic Diseases Ready for Studies with Medical Cannabis? – Results from a Digital Survey

    Jutta Richter1, Aurelia Beichert2, Tim Filla2, Matthias Schneider3, Joerg Distler4 and Inna Frohne2, 1Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Düsseldorf, Germany, 2Clinic for Rheumatology and Hiller Research Unit University Clinic Duesseldorf, Düsseldorf, Germany, 3Heinrich-Heine-Universitaet Duesseldorf, Duesseldorf, Germany, 4Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany

    Background/Purpose: There is an increasing demand from patients for medical cannabis in the German population [1]. Although medical cannabis might be used to treat pain…
  • Abstract Number: 2219 • ACR Convergence 2023

    Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis

    Dafne Capelusnik1, Elena Nikiphorou2, Annelies Boonen3, Désirée van der Heijde4, Robert BM Landewé5, Astrid van Tubergen6 and Sofia Ramiro4, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2King's College London, London, United Kingdom, 3Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, 6Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands

    Background/Purpose: In the context of the recent update of the ASAS core outcomes set (COS), the preferred comparative validity of the measurement instruments to assess…
  • Abstract Number: 0316 • ACR Convergence 2023

    Relationship of Sensitization to Pain Severity in Patients with Knee Osteoarthritis

    Lindsey MacFarlane1, Hanna Mass1, Catherine Yang1, Jose Acosta Julbe1, Antonia Chen1, Jeffrey Lange1, Morgan Jones1, Faith Selzer1, Jamie Collins1, Elena Losina2 and Jeffrey Katz1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Pain in knee osteoarthritis (OA) is multifactorial and influenced by factors including pain sensitization. Most literature on sensitization and OA has contrasted persons with…
  • Abstract Number: 0818 • ACR Convergence 2023

    Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial

    Eric Grigsby1, Stephen D. Collins2, Leonard Kapural3, Mark McBride4, Jayson Rieger5, Morgan Stokes6, Howard Rutman6 and Flavia Cicuttini7, 1Neurovations Clinical Research, Napa, CA, 2Xalud Therapeutics, Inc., Chicago, IL, 3Center for Clinical Research, Winston-Salem, NC, 4Instat Clinical Research, Chatham, NJ, 5PBM Capital, Charlottesville, VA, 6Xalud Therapeutics, Inc., Berkeley, CA, 7Monash University, Melbourne, Australia

    Background/Purpose: Interleukin (IL)-10 is a regulator of cytokine activity and has the potential to restore homeostasis in osteoarthritis (OA) of the knee. Unfortunately, relatively short…
  • Abstract Number: 1194 • ACR Convergence 2023

    Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain

    Kent Kwoh1, Frank Roemer2, Erin Ashbeck3 and Ali Guermazi4, 1University of Arizona, Tucson, AZ, 2Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, 3University of Arizona Arthritis Center, Tucson, AZ, 4Boston University, Boston, MA

    Background/Purpose: Subchondral bone marrow lesions (BMLs) have been associated with incident and progressive pain and reported to fluctuate along with concurrent fluctuations in symptoms. While…
  • Abstract Number: 1614 • ACR Convergence 2023

    Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial

    Caroline Maindet1, Anne Dumolard2, Mélanie Veloso2, Mario Barmaki3, Rodrigue Deleens4, Raphaël Gonon-Demoulian5, Alberta Lorenzi-Pernot6, Mireille Michel-Cherqui7, Alain Serrie8, Stanislas Velliet9 and Jean-Luc Bosson2, 1University Hospital Grenoble Alpes, Grenoble, France, 2Grenoble Alpes University Hospital, Grenoble, France, 3Médipôle Lyon Villeurbanne, Lyon, France, 4Rouen University Hospital, Rouen, France, 5Montpellier University Hospital, Montpellier, France, 6Neurology private practice, Mornant, France, 7Foch hospital, Suresnes, France, 8Paris University Hospital, Paris, Guinea, 9Valenciennes hospital, Valenciennes, France

    Background/Purpose: Fibromyalgia is a chronic syndrome with symptoms of moderate to severe intensity, including diffuse pain, fatigue, sleep disturbance, and cognitive impairment. While first-line recommendation…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology